Theravance Biopharma (NASDAQ:TBPH) Rating Lowered to Hold at Zacks Research

Theravance Biopharma (NASDAQ:TBPH) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

TBPH has been the topic of a number of other research reports. BTIG Research upped their target price on Theravance Biopharma from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, June 27th. Jones Trading upgraded Theravance Biopharma to a “strong-buy” rating and set a $24.00 target price on the stock in a research report on Tuesday, June 17th. B. Riley initiated coverage on Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price on the stock. Finally, Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Theravance Biopharma has a consensus rating of “Buy” and a consensus target price of $23.00.

Theravance Biopharma Stock Down 3.7%

Shares of NASDAQ TBPH opened at $13.87 on Monday. The business’s 50 day moving average price is $12.51 and its 200 day moving average price is $10.67. The firm has a market cap of $698.49 million, a P/E ratio of 57.79 and a beta of 0.05. Theravance Biopharma has a 52 week low of $7.88 and a 52 week high of $14.55.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 10,000 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the completion of the transaction, the senior vice president directly owned 326,918 shares in the company, valued at approximately $3,723,596.02. This represents a 2.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by insiders.

Institutional Trading of Theravance Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its position in shares of Theravance Biopharma by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 2,080,463 shares of the biopharmaceutical company’s stock worth $18,579,000 after purchasing an additional 69,919 shares during the last quarter. Park West Asset Management LLC boosted its holdings in Theravance Biopharma by 0.6% during the 1st quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock valued at $16,112,000 after acquiring an additional 11,256 shares during the period. Geode Capital Management LLC boosted its holdings in Theravance Biopharma by 0.4% during the 2nd quarter. Geode Capital Management LLC now owns 893,983 shares of the biopharmaceutical company’s stock valued at $9,863,000 after acquiring an additional 3,416 shares during the period. Bank of America Corp DE boosted its holdings in Theravance Biopharma by 16.5% during the 2nd quarter. Bank of America Corp DE now owns 539,645 shares of the biopharmaceutical company’s stock valued at $5,952,000 after acquiring an additional 76,417 shares during the period. Finally, Nuveen Asset Management LLC boosted its holdings in Theravance Biopharma by 10.9% during the 4th quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company’s stock valued at $4,665,000 after acquiring an additional 48,635 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.